Why the study?
New analytical methods to monitor manufactured AAV vector quality require homogeneous analytical standards with high molecular weight comparable to an AAV capsid mass.
The development of an AAV1-VP3-only capsid provides a homogeneous analytical benchmark standard for characterizing and monitoring the quality of manufactured AAV vectors in clinical gene delivery.
AAV analytics require homogeneous standards; leaves open their development for reliable clinical vector characterization.
Adeno-associated viruses (AAVs) are non-enveloped ssDNA icosahedral T = 1 viruses used as vectors for clinical gene delivery. Currently, there are over 200 AAV-related clinical trials and six approved biologics on the market. As such new analytical methods are continually being developed to characterize and monitor the quality and purity of manufactured AAV vectors, these include ion-exchange chromatography and Direct Mass Technology. However, these methods require homogeneous analytical standards with a high molecular weight standard comparable to the mass of an AAV capsid. Described here is the design, production, purification, characterization, and the cryo-electron microscopy structure of an AAV1-VP3-only capsid that fulfills this need as a calibrant to determine capsid mass, charge, homogeneity, and transgene packaging characteristics.
No takes yet. Share an insight, caveat, or question.
Mietzsch et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: